Integrating necroptosis into pan-cancer immunotherapy: a new era of personalized treatment
IntroductionNecroptosis has emerged as a promising biomarker for predicting immunotherapy responses across various cancer types. Its role in modulating immune activation and therapeutic outcomes offers potential for precision oncology. MethodsA comprehensive pan-cancer analysis was performed using b...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1510079/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846136196506320896 |
|---|---|
| author | Yan Gao Sheng Chen Lei Li |
| author_facet | Yan Gao Sheng Chen Lei Li |
| author_sort | Yan Gao |
| collection | DOAJ |
| description | IntroductionNecroptosis has emerged as a promising biomarker for predicting immunotherapy responses across various cancer types. Its role in modulating immune activation and therapeutic outcomes offers potential for precision oncology. MethodsA comprehensive pan-cancer analysis was performed using bulk RNA sequencing data to develop a necroptosis-related gene signature, termed Necroptosis.Sig. Multi-omics approaches were employed to identify critical pathways and key regulators of necroptosis, including HMGB1. Functional validation experiments were conducted in A549 lung cancer cells to evaluate the effects of HMGB1 knockdown on tumor proliferation and malignancy. ResultsThe Necroptosis.Sig gene signature effectively predicted responses to immune checkpoint inhibitors (ICIs). Multi-omics analyses highlighted HMGB1 as a key modulator of necroptosis, with potential to enhance immune activation and therapeutic efficacy. Functional experiments demonstrated that HMGB1 knockdown significantly suppressed tumor proliferation and malignancy, reinforcing the therapeutic potential of targeting necroptosis. DiscussionThese findings underscore the utility of necroptosis as a biomarker to guide personalized immunotherapy strategies. By advancing precision oncology, necroptosis provides a novel avenue for improving cancer treatment outcomes. |
| format | Article |
| id | doaj-art-b24b0a2c378e4ff8b0967a97c1b85e26 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-b24b0a2c378e4ff8b0967a97c1b85e262024-12-09T08:14:40ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-12-011510.3389/fimmu.2024.15100791510079Integrating necroptosis into pan-cancer immunotherapy: a new era of personalized treatmentYan Gao0Sheng Chen1Lei Li2Department of Respiratory and Critical Care Medicine, The Affiliated Huai’an Hospital of Xuzhou Medical University, Huai’an, ChinaDepartment of Thoracic Surgery, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, ChinaDepartment of Thoracic Surgery, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, ChinaIntroductionNecroptosis has emerged as a promising biomarker for predicting immunotherapy responses across various cancer types. Its role in modulating immune activation and therapeutic outcomes offers potential for precision oncology. MethodsA comprehensive pan-cancer analysis was performed using bulk RNA sequencing data to develop a necroptosis-related gene signature, termed Necroptosis.Sig. Multi-omics approaches were employed to identify critical pathways and key regulators of necroptosis, including HMGB1. Functional validation experiments were conducted in A549 lung cancer cells to evaluate the effects of HMGB1 knockdown on tumor proliferation and malignancy. ResultsThe Necroptosis.Sig gene signature effectively predicted responses to immune checkpoint inhibitors (ICIs). Multi-omics analyses highlighted HMGB1 as a key modulator of necroptosis, with potential to enhance immune activation and therapeutic efficacy. Functional experiments demonstrated that HMGB1 knockdown significantly suppressed tumor proliferation and malignancy, reinforcing the therapeutic potential of targeting necroptosis. DiscussionThese findings underscore the utility of necroptosis as a biomarker to guide personalized immunotherapy strategies. By advancing precision oncology, necroptosis provides a novel avenue for improving cancer treatment outcomes.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1510079/fullnecroptosismachine learningpan-cancer analysisimmune microenvironmentimmunotherapy |
| spellingShingle | Yan Gao Sheng Chen Lei Li Integrating necroptosis into pan-cancer immunotherapy: a new era of personalized treatment Frontiers in Immunology necroptosis machine learning pan-cancer analysis immune microenvironment immunotherapy |
| title | Integrating necroptosis into pan-cancer immunotherapy: a new era of personalized treatment |
| title_full | Integrating necroptosis into pan-cancer immunotherapy: a new era of personalized treatment |
| title_fullStr | Integrating necroptosis into pan-cancer immunotherapy: a new era of personalized treatment |
| title_full_unstemmed | Integrating necroptosis into pan-cancer immunotherapy: a new era of personalized treatment |
| title_short | Integrating necroptosis into pan-cancer immunotherapy: a new era of personalized treatment |
| title_sort | integrating necroptosis into pan cancer immunotherapy a new era of personalized treatment |
| topic | necroptosis machine learning pan-cancer analysis immune microenvironment immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1510079/full |
| work_keys_str_mv | AT yangao integratingnecroptosisintopancancerimmunotherapyaneweraofpersonalizedtreatment AT shengchen integratingnecroptosisintopancancerimmunotherapyaneweraofpersonalizedtreatment AT leili integratingnecroptosisintopancancerimmunotherapyaneweraofpersonalizedtreatment |